Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout
THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- #biotech--Dyve Biosciences, a research and drug development company using proprietary science to create novel therapeutics, today announced it has enrolled its first patient in TARGETS, a Phase 2 clinical study of DYV-700, the company?s topically administered therapeutic being developed as a treatment for acute gout. Lisa Misell, Ph.D., Vice President of Clinical and Medical Affairs at Dyve said, ?DYV-700 is the first therapeutic using our proprietary science to re
